Home > Browse Issues > Vol.37 No.1
Antibody Therapeutics that Target Cancer Stem Cells (CSCs)—for Some Signal Pathways and CSCs Markers
Li Hongrui1, Ding Qian1, Chen Shuqing2, Zhan Jinbiao1*
1Department of Biochemistry, School of Medicine, Zhejiang University, Hangzhou 310058, China;2College of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, China)
Abstract: Cancer stem cells (CSCs) are defined as a kind of undifferentiated cells that can self-renew and differentiate. Like normal stem cells， the CSCs also have multipotency capable of differentiating into different cancer cells with heterogeneity， and are usually resistant to the traditional drug therapies. The differences between CSCs and normal stem cells are the abnormal activation of some signal pathways and the expression of different biomarkers. Targeting the differences， scientists come up with some strategies to kill CSCs， such as using antibodies targeting the CSC markers or signal pathways to stop the growth or activating the apoptosis of CSCs. This review focuses on antibody drugs which target on the CSC-related signal pathways such as Notch and Wnt， and CSCs markers such as EpCAM and CD44， aiming at further developing these novel immunotherapeutics.
CN
EN